Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 181
- Registration Number
- NCT03505710
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine at St. Louis, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT03384940
- Locations
- 🇺🇸
UCLA Health, Santa Monica, California, United States
🇮🇹Oncology Institute Veneto IOV-IRCCS, Padova, Ferrara, Italy
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03383692
- Locations
- 🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Hokkaido, Japan
🇯🇵Kobe University Hospital, Kobe, Hyogo, Japan
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-11-03
- Target Recruit Count
- 12
- Registration Number
- NCT03368196
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
- First Posted Date
- 2017-12-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT03366428
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵Shizuoka Cancer Center, Shizuoka, Japan
🇯🇵Toranomon Hospital, Minato-Ku, Tokyo, Japan
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 531
- Registration Number
- NCT03334617
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 233
- Registration Number
- NCT03329690
- Locations
- 🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Fukuoka, Japan
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 253
- Registration Number
- NCT03248492
- Locations
- 🇺🇸
The Regents of the University of California, Los Angeles, California, United States
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.